NASDAQ:CDNA

CareDx (CDNA) Stock Forecast, Price & News

$6.62

-0.33 (-4.75%)

(As of 10:08 AM ET)

Compare

Today's Range: $6.62
▼
$6.95
50-Day Range: $6.86
▼
$11.26
52-Week Range: $6.22
▼
$20.71

Volume: 103,374 shs
Average Volume: 1.02 million shs
Market Capitalization: $358.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.80

CareDx MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 98.6% Upside
$13.80 Price Target
Short Interest: Healthy
7.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.58
Based on 6 Articles This Week
Insider Trading: Selling Shares
$189,377 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.18) to ($2.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

534th out of 965 stocks

Medical Laboratories Industry

14th out of 25 stocks

3.2

Analyst's Opinion

Consensus Rating
CareDx has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.80, CareDx has a forecasted upside of 98.6% from its current price of $6.95.
Amount of Analyst Coverage
CareDx has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
7.20% of the outstanding shares of CareDx have been sold short.
Short Interest Ratio / Days to Cover
CareDx has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in CareDx has recently decreased by 5.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CareDx does not currently pay a dividend.
Dividend Growth
CareDx does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.
Environmental Sustainability
The Environmental Impact score for CareDx is -0.66.

2.0

News and Social Media Coverage

News Sentiment
CareDx has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for CareDx this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $189,377.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of CareDx is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CareDx are expected to decrease in the coming year, from ($2.18) to ($2.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CareDx is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CareDx is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CareDx has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Price History

30 days | 90 days | 365 days | Advanced Chart

CDNA Stock News Headlines

October 3, 2023 | finance.yahoo.com

CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents

October 3, 2023 | americanbankingnews.com

CareDx, Inc (NASDAQ:CDNA) Insider Sells $19,472.38 in Stock

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

October 2, 2023 | reuters.com

US Supreme Court rebuffs CareDx patent lawsuit over organ-rejection tests

September 27, 2023 | msn.com

Stephens & Co. Reiterates Caredx (CDNA) Equal-Weight Recommendation

September 27, 2023 | americanbankingnews.com

CareDx's (CDNA) "Equal Weight" Rating Reaffirmed at Stephens

September 19, 2023 | finance.yahoo.com

CareDx To Present at the 2023 Cantor Global Healthcare Conference

September 14, 2023 | finance.yahoo.com

CareDx Advances Global Transplant Patient Care at ESOT Congress 2023

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

August 31, 2023 | msn.com

Caredx (CDNA) Price Target Increased by 8.00% to 11.02

August 31, 2023 | finance.yahoo.com

CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 17, 2023 | finance.yahoo.com

CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care

August 15, 2023 | msn.com

Raymond James Upgrades Caredx (CDNA)

August 15, 2023 | finance.yahoo.com

CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 13% this week, taking three-year losses to 73%

August 11, 2023 | finance.yahoo.com

CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection

August 10, 2023 | msn.com

HC Wainwright & Co. Reiterates Caredx (CDNA) Neutral Recommendation

August 9, 2023 | finance.yahoo.com

Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics

August 8, 2023 | finance.yahoo.com

CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2023 | finance.yahoo.com

CareDx Reports Second Quarter 2023 Results

August 7, 2023 | finance.yahoo.com

CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test

August 4, 2023 | bizjournals.com

Scott Plank's organ transplant company MediGO sells to California company

August 3, 2023 | markets.businessinsider.com

Craig-Hallum Reaffirms Their Hold Rating on CareDx (CDNA)

August 3, 2023 | finance.yahoo.com

CareDx to Report Second Quarter 2023 Financial Results

August 2, 2023 | msn.com

CareDx gains on Medicare coverage for HeartCare test

August 2, 2023 | finance.yahoo.com

CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance

July 28, 2023 | seekingalpha.com

CareDx: Regulatory Uncertainties Impacting Revenue

July 25, 2023 | in.investing.com

CareDx stock surges on the acquisition of MediGO

See More Headlines

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Company Calendar

Last Earnings: 8/08/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDNA
CUSIP: N/A
CIK: 1217234
Web: www.caredxinc.com
Phone: (415) 287-2300
Fax: 415-287-2450
Employees: 727
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.80
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +98.6%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,610,000.00
Net Margins: -27.15%
Pretax Margin: -26.99%
Return on Equity: -19.84%
Return on Assets: -15.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.84
Quick Ratio: 4.59

Sales & Book Value

Annual Sales: $309.31 million
Price / Sales: 1.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.05 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 54,169,000
Free Float: 51,894,000
Market Cap: $376.47 million
Optionable: Optionable
Beta: 1.02

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Reginald Seeto M.D. (Age 51)
MBBS, Pres, CEO & Director
Comp: $954.71k

Mr. Abhishek Jain (Age 46)
CFO & Principal Accounting Officer
Comp: $425.58k

Mr. Abraham Ronai Esq. (Age 49)
Chief Admin. & Legal Officer and Sec.
Comp: $566.49k

Dr. Peter Maag Ph.D. (Age 56)
Exec. Director
Comp: $43.23k

Ms. Sasha King M.B.A. (Age 37)
Exec. Officer
Comp: $343.34k

Mr. Alexander L. Johnson (Age 48)
Pres of Patient and Testing Services
Comp: $547.43k

Ms. Marica Grskovic Ph.D.
Chief Operating Officer

Mr. Ian Cooney
VP of Investor Relations

Dr. Mickey Y. Kim M.D.
Sr. VP of Corp. Devel. & Head of Global Product

Mr. Jarrod Borkat
Sr. VP and Head of Marketing & Portfolio Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDNA Stock - Frequently Asked Questions

Should I buy or sell CareDx stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CDNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDNA, but not buy additional shares or sell existing shares.
View CDNA analyst ratings or view top-rated stocks.
What is CareDx's stock price forecast for 2023?: 6 brokerages have issued 1-year target prices for CareDx's stock. Their CDNA share price forecasts range from $9.00 to $25.00. On average, they expect the company's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price.
View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts.
How have CDNA shares performed in 2023?: CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 39.1% and is now trading at $6.95.
View the best growth stocks for 2023 here.
Are investors shorting CareDx?: CareDx saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 3,900,000 shares, a decline of 5.8% from the August 31st total of 4,140,000 shares. Based on an average daily trading volume, of 835,900 shares, the days-to-cover ratio is presently 4.7 days.
View CareDx's Short Interest.
When is CareDx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CDNA earnings forecast.
How were CareDx's earnings last quarter?: CareDx, Inc (NASDAQ:CDNA) announced its earnings results on Tuesday, August, 8th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.10. The business earned $70.30 million during the quarter, compared to the consensus estimate of $56.40 million. CareDx had a negative trailing twelve-month return on equity of 19.84% and a negative net margin of 27.15%.
What ETFs hold CareDx's stock?: ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has CareDx issued on next quarter's earnings?: CareDx issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240.00 million-$260.00 million, compared to the consensus revenue estimate of $261.94 million.
What other stocks do shareholders of CareDx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).
What is CareDx's stock symbol?: CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How do I buy shares of CareDx?: Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CareDx's stock price today?: One share of CDNA stock can currently be purchased for approximately $6.95.
How much money does CareDx make?: CareDx (NASDAQ:CDNA) has a market capitalization of $376.47 million and generates $309.31 million in revenue each year. The company earns $-76,610,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.
How many employees does CareDx have?: The company employs 727 workers across the globe.
How can I contact CareDx?: CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial